Compare ELSE & PHIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELSE | PHIO |
|---|---|---|
| Founded | 1968 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.5M | 14.6M |
| IPO Year | 1995 | 2011 |
| Metric | ELSE | PHIO |
|---|---|---|
| Price | $4.48 | $1.25 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $10.67 |
| AVG Volume (30 Days) | 1.1K | ★ 393.0K |
| Earning Date | 05-11-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.50 | N/A |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $9,373,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $74.17 | ★ N/A |
| Revenue Growth | ★ 9.56 | N/A |
| 52 Week Low | $3.65 | $0.81 |
| 52 Week High | $5.29 | $4.19 |
| Indicator | ELSE | PHIO |
|---|---|---|
| Relative Strength Index (RSI) | 56.07 | 54.71 |
| Support Level | $4.08 | $0.99 |
| Resistance Level | $4.72 | $1.43 |
| Average True Range (ATR) | 0.06 | 0.08 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 76.56 | 62.94 |
Electro-Sensors Inc manufactures and sells industrial production monitoring and process control systems. It manufactures a complete line of monitoring and control systems for a wide range of industrial machine applications. The systems measure machine production and operation rates, as well as regulate the speed of related machines in production processes. Its products include motor drive control, position monitors, sensor targets, signal conditioners, speed sensors, speed switches, tachometers, temperature sensors, vibration monitors, etc.
Phio Pharmaceuticals Corp is a clinical-stage biopharmaceutical company whose proprietary INTASYL small-interfering RNA gene silencing technology is designed to make immune cells more effective in killing tumor cells. Its pipeline programs are PH-762 and PH-894. The group is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems. It is committed to discovering and developing cancer treatments for patients by creating new pathways toward a cancer-free future. The Company operates with a single operating segment, the Clinical segment, and all assets are located in the United States.